A
grade
Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis.
Orforglipron (LY-3502970) · europepmc · Meta-analysis
Orforglipron may lead to meaningful reductions in BMI and HbA1c, particularly at higher doses, but comes with increased rates of adverse events and treatment discontinuation.
-3.52 kg/m² BMI reduction at 45 mg vs placebo.